ArticlePediatric blood & cancer2022
Feasibility of oncology clinical trial-embedded evaluation of social determinants of health.
Article in Pediatric blood & cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Supplemental Nutrition Assistance Program participation gaps within a pediatric leukemia clinical trial cohort.Pediatric blood & cancer · 2024Trial
- ASSIST: Refinement of a Benefits Navigator Intervention Among Low-Income Pediatric Oncology Families.Pediatric blood & cancer · 2026Article
- Prevalence and Trajectory of Household Material Hardship Among Children With Advanced Cancer.Pediatric blood & cancer · 2026Article
- Pediatric Oncology Clinical Trial Participation Among Families From Historically Marginalized Groups.JAMA network open · 2026Article
- Collecting Social Determinants of Health in a Children's Oncology Group Trial for High-Risk Neuroblastoma.JAMA network open · 2026Article
- Enrollment in Children's Oncology Group's clinical trials: population-based linkage with the National Childhood Cancer Registry.Journal of the National Cancer Institute · 2025Article
- Incorporation of patient-reported outcomes in pediatric cancer clinical trials: design, implementation, and dissemination.Journal of the National Cancer Institute · 2025Article
- Targeting hardship: poverty as a modifiable risk factor in childhood leukemia and lymphoma treatment.Hematology. American Society of Hematology. Education Program · 2024Review
- Population-Based Data Linkage Describing Patterns of Cancer Clinical Trial Enrollment Among Children and Adolescents.JCO oncology practice · 2024Article
- Article
- Inequitable Poverty Exposures: A Subspecialty Opportunity to Address Disparities.Hospital pediatrics · 2024Article
- A comprehensive analysis of neuroblastoma incidence, survival, and racial and ethnic disparities from 2001 to 2019.Pediatric blood & cancer · 2024Article
- Disparities in parental distress in a multicenter clinical trial for pediatric acute lymphoblastic leukemia.Journal of the National Cancer Institute · 2023Article
- Children's Oncology Group's 2023 blueprint for research: Epidemiology.Pediatric blood & cancer · 2023Article
- Children's Oncology Group's 2023 blueprint for research: Behavioral science.Pediatric blood & cancer · 2023Article
- "It's a lot of things": Household material hardship among Black and Hispanic parents of children with cancer.Pediatric blood & cancer · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
Social determinants of health (SDoH) are associated with stark disparities in cancer outcomes, but systematic SDoH data collection is virtually absent from oncology clinical trials. Trial-based SDoH data are essential to ensure representation of marginalized populations, contextualize outcome disparities, and identify health-equity intervention opportunities. We report the feasibility of a pediatric oncology multicenter therapeutic trial-embedded SDoH investigation. Among 448 trial participants, 392 (87.5%) opted-in to the embedded SDoH study; 375 (95.7%) completed baseline surveys, with high longitudinal response rates (88.9-93.1%) over 24 months. Trial-embedded SDoH data collection is feasible and acceptable and must be consistently included within future oncology trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.